Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

The company's shares are trading at their lowest since August 2023. Source: xStation
Market Wrap: European software stocks keep indices near record highs. Dollar gives up this week's gains (14.08.2026)
Reddit joins the S&P 500, shares surge 12% 📈 From a niche forum to the heart of Wall Street
Daily Summary: S&P 500 at a New ATH (13.08.2026)
US Open: S&P 500 close to highs - as September Fed hike chances fall (13.08.2026)